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Background:  Percutaneous pulmonary valve implantation (PPVI) has emerged as a highly effective alternative to surgical revision in 
congenital heart disease patients with right ventricle outflow tract (RVOT) stenosis and/or regurgitation. Reports of safety outcomes in PPVI 
vary widely in the literature, likely due to heterogeneity in patient characteristics and surgical substrates. We aimed to perform a systematic 
review of adverse events following PPVI and estimate the overall incidence of PPVI complications.
methods:  PubMed, EMBASE and Cochrane Central were searched for studies that reported procedural and long-term complications 
of PPVI. No restrictions were made to the type of valve used (Melody/Edwards SAPIEN). Baseline demographic and surgical data were 
collected. The overall rate of PPVI complications was calculated amongst all studies that met inclusion criteria.
results:  A total of 19 studies and 1,151 patients were included. The most common complication observed was stent fracture, seen 
in 12.9% of patients. Surgical conversion was required in 1.5% of PPVI procedures. In a follow up that ranged from 4 to 30 months, 
reintervention and explantation were needed in 10% and 4.6% of cases, respectively. The incidence of bacterial endocarditis and RVOT 
tear was 2.9% each. Other complications of PPVI occurred in less than 1% of cases and include: guidewire injury, perforation of the 
pulmonary artery branches, hemothorax, valve embolization, stent migration, and ventricular arrhythmias. Procedure-related mortality was 
exceedingly rare and occurred in only 3 patients (0.3%).
Conclusion:  In summary, we report the overall rate of complications following PPVI in pooled data from previously published studies. 
The inclusion of heterogeneous patient populations with different sample sizes and baseline characteristics increases the validity of our 
findings. These results can be used by physicians and patients in the evaluation of risks and benefits associated with PPVI.
